BCR and chronic myelogenous leukemia, BCR-ABL1 positive: However, BCR–ABL kinase inhibition or STAT5 knockdown can only partially reduce SIRT1 expression, suggesting that other kinase-independent mechanisms are responsible for increased SIRT1 activity in CML [19].